Deferred Tax Assets, Valuation Allowance of Spyre Therapeutics, Inc. from 31 Dec 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Spyre Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2015 to 31 Dec 2025.
  • Spyre Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $201,345,000, a 24% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Spyre Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $201,345,000 +$38,416,000 +24% 31 Dec 2025 10-K 19 Feb 2026 2025 FY
Q4 2024 $162,929,000 +$37,438,000 +30% 31 Dec 2024 10-K 19 Feb 2026 2025 FY
Q4 2023 $125,491,000 +$17,839,000 +17% 31 Dec 2023 10-K 19 Feb 2026 2025 FY
Q4 2022 $107,652,000 +$20,609,000 +24% 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q4 2021 $87,043,000 +$16,900,000 +24% 31 Dec 2021 10-K 02 Mar 2023 2022 FY
Q4 2020 $70,143,000 +$20,662,000 +42% 31 Dec 2020 10-K 08 Mar 2022 2021 FY
Q4 2019 $49,481,000 +$20,359,000 +70% 31 Dec 2019 10-K 18 Mar 2021 2020 FY
Q4 2018 $29,122,000 +$9,796,000 +51% 31 Dec 2018 10-K 24 Feb 2020 2019 FY
Q4 2017 $19,326,000 +$2,673,000 +16% 31 Dec 2017 10-K 07 Mar 2019 2018 FY
Q4 2016 $16,653,000 +$9,369,000 +129% 31 Dec 2016 10-K 13 Mar 2018 2017 FY
Q4 2015 $7,284,000 31 Dec 2015 10-K 23 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.